Health & Fitness
Mon, May 10, 2010Sun, May 9, 2010Sat, May 8, 2010Fri, May 7, 2010Thu, May 6, 2010Mon, January 11, 2010Sat, January 9, 2010Fri, January 8, 2010Enzon to Release First Quarter 2010 Earnings on Monday, May 10, 2010; Conference Call and Webcast to Follow
//health-fitness.news-articles.net/content/2010/ .. -2010-conference-call-and-webcast-to-follow.html
Published in Health and Fitness on Thursday, May 6th 2010 at 19:40 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
BRIDGEWATER, N.J.--([ BUSINESS WIRE ])--Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended March 31, 2010, on Monday, May 10, 2010 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 5:00 pm Eastern Time (ET) on Monday, May 10, 2010.
All interested parties may access the call by using the following information:
| Domestic Dial-In Number: | (877) 561-2748 | |
| International Dial-In Number: | (720) 545-0044 | |
| Access Code: | Enzon | |
The call will also be available live audio webcast at [ http://investor.enzon.com/eventdetail.cfm?eventid=81017 ]. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Tuesday, May, 11, 2010 at approximately 8:00 am Eastern Time (ET) and end on Monday, May 17, 2010 at approximately 12:00 pm Eastern Time (ET). It may be accessed using the following information:
| Domestic Dial-In Number: | (800) 642-1687 | |
| International Dial-In Number: | (706) 645-9291 | |
| Conference I.D.: | 72973072 | |
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative medicines for patients with cancer. Enzona™s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform, Customized Linker technologya" and mRNA antagonists using the Locked Nucleic Acida" (LNA) technology. Enzona™s receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology. Further information about Enzon and this press release can be found on the Companya™s web site at [ www.enzon.com ].